Natixis pledges its continued support to the Gustave Roussy Foundation
Natixis has been committed supporter of the Gustave Roussy Foundation since 2011 and has renewed its sponsorship for three new research projects over a three-year period.
Precision medicine: the MATCH-R trial to understand resistance to new treatments
Natixis is involved in a trial precision medicine research project called MATCH-R. The aim of the trial, which is being headed up by Professors Jean-Charles Soria and Fabrice André, is to understand how cancerous cells adapt to targeted therapies and immunotherapies by developing resistance mechanisms.
For cancer sufferers who are being treated with a targeted therapy or immunotherapy for a metastasis and who have developed a resistance to treatment, the protocol of the future MATCH-R clinical trial involves taking a biopsy of their tumour and a blood sample. Their molecular portraits are established to identify genetic mutations in the resistance. The trial aims to test a total of 600 patients over five years. Natixis will fund the patients’ new molecular portraits and those specifically realized on circulating tumour DNA.
Fundamental research: Immunotherapy and DNA repair
Natixis is also assisting two new fundamental research teams with their work in promising oncology fields: immunology and DNA repair.
Sébastien Apcher’s team is specifically working on tumour immunology and immunotherapy against cancer.
Until now, cancer treatments have targeted the tumour to destroy it, with chemotherapy being one of the main strategies. Immunotherapy targets the body’s immune system to strengthen and stimulate the patient’s defences against cancer cells. Antibodies now can halt the spread of extremely aggressive tumours for which there were previously only few therapeutic solutions.
Further out, the work of Sébastien Apcher’s team may help lead to a therapeutic vaccine to help the immune system recognize and destroy tumour cells. The vaccine will enhance the action of cancer drugs.
Gérard Mazon’s team is studying the repair mechanisms of DNA double-strand breaks to understand how and why problems occur in the repair process and their possible role in triggering cancer.
Looking forward, the identification of mutations in the DNA repair pathways that can lead to cancer may be used as a target for synthetic lethality strategies. This would also benefit the population of predictive tests to screen cancers long before they mutate into more aggressive types of tumours.
|The Gustave Roussy Foundation was created in 2005 to fund cancer research conducted at the Gustave Roussy Cancer Center. Its overriding mission is to improve the quality of care and the life of patients treated there.|